Oncotarget

Reviews:

shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy

Jie Zhang, Meng Ding, Kai Xu, Lijun Mao and Junian Zheng _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:29824-29834. https://doi.org/10.18632/oncotarget.8035

Metrics: PDF 793 views  |   HTML 1322 views  |   ?  


Abstract

Jie Zhang1, Meng Ding1, Kai Xu1, Lijun Mao1,2 and Junian Zheng1

1 Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, China

2 Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, China

Correspondence:

Lijun Mao, email:

Junian Zheng, email:

Keywords: conditionally replicating adenoviruses, RNA interference, cancer, target therapy

Received: December 09, 2015 Accepted: February 15, 2016 Published: March 10, 2016

Abstract

The small-interfering RNAs (siRNAs) have been employed to knockdown the expression of cancer-associated genes and shown some promise in cancer therapy. However, synthetic siRNA duplexes or plasmid mediated delivery of siRNAs have several problems, such as short half-life, low transfection efficiency and cytotoxicity associated with transfection. Conditionally replicating adenovirus (CRAds) as the delivery vector for short hairpin RNAs (shRNAs) could overcome these limitations and have shown augmented anti-tumor effects in experimental studies and preclinical trials. In this review, we summarize recent progress in the development of CRAds-shRNA for cancer treatment. Combination of CRAds-shRNA with chemotherapeutics, radiation, dendritic cells, monoclonal antibodies and small-molecule inhibitors will be necessary to eradicate cancer cells and cancer stem cells and achieve superior outcomes. The use of CRAd platform for efficient delivery of shRNAs and foreign genes will open a new avenue for cancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8035